Multichannel
Building capacity in digital
Making the transition to digital-first commercial operations remains a work-in-progress for most pharma companies. It’s a...
Patients and Medical
The value in measuring the patient experience
Gathering evidence directly from patients is a new endeavour for many, but it has great potential value in generating evidence and...
Latest
-
MultichannelThe new era of digital-first engagement demands new approaches to scaling by harnessing technology, seeing content creation as collaborative and cultivating a startup culture
-
Access and Evidence
Bringing innovation to rare disease patients in Europe
Johanna Friedl-Naderer, President, Europe, Canada & Partner Markets, Biogen on how collaboration between governments and industry can lead to better patient outcomes. -
Access and Evidence
#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021
To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021 -
Clinical
Trial site management in the post pandemic era
The impacts of 2020 on trials are causing pharma to consider a new direction for trial sites, taking them closer to the patient -
Patients and Medical
Better research through patient insights
AstraZeneca’s innovations in chronic kidney disease are pointing the way to new ways of involving patients and RWE to drive new insights and better outcomes
Most Popular
Joseph Constance, (Jan 6, 2021)
Broader and deeper outreach, along with RWE, are some of the methods pharma is using to widen trials participation
Izzy Gladstone, (Feb 11, 2021)
To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021

Izzy Gladstone, (Feb 17, 2021)
Johanna Friedl-Naderer, President, Europe, Canada & Partner Markets, Biogen on how collaboration between governments and industry can lead to better patient outcomes.

Opinion
Jill Donahue, (Oct 2, 2020)
Pfizer's Medical Affairs Lead, Rare Diseases, talks about purpose, patients and pharma's power to do good

Jill Donahue, (Apr 14, 2020)
Merck's Thomas D’Hooghe shares his thoughts on passion, purpose, leading people and making a difference

Commercial
-
Blended and augmented: Reimagining the role of the rep
The events of 2020 have compelled pharma to reimagine the role of the rep to better adapt to the new rules of engagement -
Uncorking the compliance bottlenecks in digital
The sudden demand for digital content this year has created serious compliance bottlenecks that pharma is racing to overcome with new processes and technology -
Creating a holistic customer experience
Finding solutions to unmet customer needs means harnessing the combined power of medical and marketing skills – and creating a culture to match -
Adapting to the multichannel imperative: A special report
Pharma’s gradual evolution into digital-first commercial has become urgent in the COVID-19 world. A comprehensive multi-channel approach including the use of digital tools to enhance customer engagement will transform pharma sales. -
Australia’s field force: evolving on fast forward
Australian pharma’s field force roles are changing fast and the new digital-first environment is driving a need for new approaches and new skillsets
Access and Evidence
-
A burning desire to make a difference for patients
Annexus Health, eyeforpharma’s 2020 Health Start-up winner is on a mission for patients -
From reactive to predictive: Concerto’s new compositions
Artificial Intelligence has only just begun to unlock high value innovation. The latest predictive tools will break new ground, says Concerto HealthAI’s Jeff Elton -
Evolving HTA frameworks to accelerate innovation
Iterative evidence generation and demonstrating value over time could help unlock delays in getting cures out, saving more lives, says Janssen’s Clare Hague -
Can we afford to pay for future cures?
Medical innovation is racing ahead of healthcare’s ability to innovate on payments, but new ideas are emerging -
Advancing RWE together with academia
Pharma can realise the potential of RWE faster by collaborating more effectively with academia but first it must build trust
Patients and Medical
-
The value in measuring the patient experience
Pharma can improve outcomes, products and HCP relationships using technology to capture patients’ day-to-day experience of their disease -
Better research through patient insights
AstraZeneca’s innovations in chronic kidney disease are pointing the way to new ways of involving patients and RWE to drive new insights and better outcomes -
Building a health equity culture
Health inequities, often a legacy of racism, lie heavy on the healthcare sector in the US and beyond. Fixing the problem will require long-term effort on multiple fronts -
Digital companions: helping improve patient treatment journeys
The virtual health explosion isn't going away. This just at the start of an era of digital enhancement -
Racially diverse clinical trials: A new patient-led legacy takes root
Attempts to make trials more diverse aren’t working. To overcome far-reaching inequality and deep distrust, pharma must be educated by, as well as educate, under-served communities